calendar
10 Sep, 2021
Genor Biopharma (Stock code: 6998.HK) announced today that the latest clinical data on Geptanolimab (GB226) would be presented at ESMO (European Society for Medical Oncology) Congress 2021.
1866
calendar
24 Mar, 2021
Significant progresses in IND, clinical development, NDA/BLA, commercialization, BD and financing
1731
calendar
17 Mar, 2021
SHANGHAI, China, March 17, 2021 -- Genor Biopharma (Stock code: 6998.HK) announced today that the Company has submitted a clinical trial application to the Bellberry Human Research Ethics Committee in Australia for First In Human (FIH) clinical trial of GB261, a novel CD20/CD3 bispecific antibody, in patients with B-cell non-Hodgkin Lymphoma (B-NHL).
1713
calendar
15 Mar, 2021
SHANGHAI, China, March 15, 2021 -- Genor Biopharma (Stock code: 6998.HK) announced today that Genor Biopharma was officially included into the Heng Seng Composite Index (HSCI). This was announced by Hang Seng Index Limited according to the results of its review of the Heng Seng Family of Indexes for the quarter ended 31 December 2020, and has been effective since March 15, 2021.
1710
calendar
12 Mar, 2021
SHANGHAI, China, March 12, 2021 -- Genor Biopharma (Stock code: 6998.HK) announced today IND application of GB492 (IMSA101, Stimulator of interferon genes,STING) is under review by NMPA. The Phase I/IIa clinical trials will evaluate the safety and efficacy of GB492 as monotherapy and in combination with recombinant anti-human PD-1/L1 functional monoclonal antibody, in patients with advanced treatment-refractory malignancies.
1709